Use of Sirmione in patients with chronic disorders of cerebral circulation
Abstract
Chronic disorders of cerebral circulation are a common cause of increasing disability and the onset of death. Ensuring the effective treatment of such patients with secondary prevention measures requires an understanding of the pathophysiological mechanisms of the development of the disease. Issues of pathogenesis and classification of chronic disorders of cerebral circulation are discussed. The expediency of using drugs with such ability to improve cerebral blood flow and restore autoregulation of cerebral circulation was noted in such a contingent of patients. Information on the possibility of using the drug Sermion (nicergoline) in the treatment of patients with chronic forms of cerebrovascular pathology is given.
About the Authors
P. R. Kamchatnov
Russian National Research Medical University n.a. N. I. Pirogov
Russian Federation
Russian Federation
A. V. Chugunov
Russian National Research Medical University n.a. N. I. Pirogov
Russian Federation
Russian Federation
A. B. Abusueva
Dagestan State Medical University
Russian Federation
Russian Federation
Yu. A. Morozova
Municipal Polyclinic No. 62, Moscow
Russian Federation
Russian Federation
References
1. Гусев Е. И., Скворцова В. И. Ишемия головного мозга. М: Медицина. 2001.
2. DiCarlo A, Baldereschi M, Amaducci L, et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. J Am Ger Soc 2000; 48: 775-82.
3. Гулевская Т. С., Моргунов В. А. Патологическая анатомия нарушений мозгового кровообращения при атеросклерозе и артериальной гипертензии. М. Медицина, 2009.
4. Csiszar A., TarantiniS., Fülöp G., Tamas K. Hypertension impairs neurovascular coupling and promotes microvascular injury: role in exacerbation of Alzheimer's disease. GeroScience. 2017; 39: 359-372.
5. Brickman A., Guzman V., Gonzalez-Castellon M., Razlighi Q., Gu Y., Narkhede A., Janicki S. Cerebral autoregulation, beta-amyloid, and white matter hyperintensities are interrelated. Neurosci Lett. 2015; 592: 54-58.
6. Satoshi S., Masafumi I. Interaction between cerebrovascular disease and Alzheimer pathology. Current Opinion in Psychiatry: 2016; 29 (2): 168-173.
7. Attems J., Jellinger К. The overlap between vascular disease and Alzheimer's disease - lessons from pathology. BMC Medicine. 2014; 12: 206.
8. Жетишев Р. Р., Михайлова Н. А., Камчатнов П. Р., Иващенко Р. А. Асимптомные инфаркты головного мозга: факторы риска и когнитивные нарушения. Журн. неврол. и психиатр. им. С. С. Корсакова. Инсульт. 2014; 3 (2): 3-7.
9. Левин О. С. Алгоритмы диагностики и лечения деменции. М., МЕДпресс-информ, 2012.
10. Гусев Е.И., Боголепова А. Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М., МЕДпресс-информ, 2013.
11. Wu Y.-T. Dementia in Western Europe: epidemiological evidence and implications for policy making. The Lancet Neurology. 2016; 15 (1): 116-124.
12. Pase M. P., Beiser A., Enserro D., Xanthakis V. et al. Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia. STROKEAHA. 115.012608. Published online before print April 12, 2016, doi: 10.1161/STROKEAHA.115.012608.
13. Jones D. S., Greene J. A. Is Dementia in Decline? Historical Trends and Future Trajectories. N Engl J Med. 2016; 374:507-509.
14. Winblad B., Fioravanti M., Dolezal T. Therapeutic use of nicergoline. Clin. Drug Invest., 2008, 28: 533-52.
15. Walford T., Musa F., Harper A. Nicergoline inhibits human platelet Ca2+ signaling through triggering a microtubule-depen dent reorganization of the platelet ultrastructure. Br. J. of Pharmacol. 2016; 173: 234-247.
16. Winblad B., Carfagna N., Bonura L. Nicergoline in dementia. A review of its pharmacologicalproperties and therapeutic potential. CNS Drugs. 2000, 14: 267-87.
17. Nappi G., Bono G., Merlo P., Borromei A., Caltagirone C., Lomeo C. et al. Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia. Clin Drug Investig. 1997 Jun;13(6): 308-16.
18. Saletu B. et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology. 1995; 117(4): 385-395.
19. Pilkowska E., Jakubowska T., Witkowska K. Nicergoline in the treatment of patients after a mild ischemic stroke. Neurol Neurochir Pol. 2002; 36: 1075-85.
20. Setyopranoto I. Role of nicergoline 60 miligram per oral for improvement of the patients with acute ischemic stroke. J Neurol Sci. 2009; 285: S221-2.
21. Akisada T, Orita Y, Sato Y, et al. Effect of nicergoline on vertigo and tinnitus. Pract Otol 1994; 87: 845-55.
22. Fioravanti M., Nakashima T., Xu J. A systematic review and metaanalysis assessing adverse event profile and tolerability of nicergoline. BMJ Open. 2014; 4: e005090. doi:10.1136/ bmjopen-2014-005090.
Review
For citations:
Kamchatnov P.R., Chugunov A.V., Abusueva A.B., Morozova Yu.A. Use of Sirmione in patients with chronic disorders of cerebral circulation. Medical alphabet. 2017;3(32):45-49. (In Russ.)
Views:
1158
Email this article 